SH2D1A and slam protein expression in human lymphocytes and derived cell lines

Noémi Nagy, Cristina Cerboni, Karin Mattsson, Akihiko Maeda, P. Gogolák, János Sümegi, A. Lányi, László Székely, Ennio Carbone, George Klein, Eva Klein

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The gene defect responsible for the X-linked lymphoproliferative disease (XLP) is associated with an impaired control of Epstein-Barr virus (EBV) infection. The gene has been recently identified and the encoded protein (designated SH2D1A, DSHP or SAP) was characterized. It is a 128 amino acid (aa) protein, containing a single Src homology 2 (SH2) domain. It interacts with signaling lymphocytic activation molecule (SLAM) expressed on the surface of activated T and B cells. We show that activated T, but not activated B, cells express the SH2D1A protein. NK cells express the protein as well. Tumor lines originating from B, T or NK cells exhibited similar SH2D1A protein expression as the corresponding normal cells, with some notable exceptions. EBV-carrying, tumor phenotype representative (type I), but not EBV-carrying lymphoblastoid cell line (LCL)-like (type III) or EBV-negative Burkitt lymphoma (BL) lines expressed SH2D1A. The phenotypic switch from type I to type III in the EBV-carrying BL line Mutu was associated with a down-regulation of SH2D1A and up-regulation of SLAM. In contrast to normal ex vivo and long-term activated NK cells, 2 of 3 NK leukemia lines expressed SLAM. All 3 lines expressed SH2D1A, like their normal counterparts. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)439-447
Number of pages9
JournalInternational Journal of Cancer
Volume88
Issue number3
DOIs
Publication statusPublished - 2000

Fingerprint

Human Herpesvirus 4
Natural Killer Cells
Lymphocytes
Cell Line
B-Lymphocytes
Burkitt Lymphoma
T-Lymphocytes
Epstein-Barr Virus Infections
src Homology Domains
Lymphoproliferative Disorders
Genes
Neoplasms
Leukemia
Proteins
Up-Regulation
Down-Regulation
Phenotype
Amino Acids
Signaling Lymphocytic Activation Molecule Associated Protein
Signaling Lymphocytic Activation Molecule Family

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

SH2D1A and slam protein expression in human lymphocytes and derived cell lines. / Nagy, Noémi; Cerboni, Cristina; Mattsson, Karin; Maeda, Akihiko; Gogolák, P.; Sümegi, János; Lányi, A.; Székely, László; Carbone, Ennio; Klein, George; Klein, Eva.

In: International Journal of Cancer, Vol. 88, No. 3, 2000, p. 439-447.

Research output: Contribution to journalArticle

Nagy, N, Cerboni, C, Mattsson, K, Maeda, A, Gogolák, P, Sümegi, J, Lányi, A, Székely, L, Carbone, E, Klein, G & Klein, E 2000, 'SH2D1A and slam protein expression in human lymphocytes and derived cell lines', International Journal of Cancer, vol. 88, no. 3, pp. 439-447. https://doi.org/10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#
Nagy, Noémi ; Cerboni, Cristina ; Mattsson, Karin ; Maeda, Akihiko ; Gogolák, P. ; Sümegi, János ; Lányi, A. ; Székely, László ; Carbone, Ennio ; Klein, George ; Klein, Eva. / SH2D1A and slam protein expression in human lymphocytes and derived cell lines. In: International Journal of Cancer. 2000 ; Vol. 88, No. 3. pp. 439-447.
@article{20a7052f5e404833b53cf4a22e38fcd8,
title = "SH2D1A and slam protein expression in human lymphocytes and derived cell lines",
abstract = "The gene defect responsible for the X-linked lymphoproliferative disease (XLP) is associated with an impaired control of Epstein-Barr virus (EBV) infection. The gene has been recently identified and the encoded protein (designated SH2D1A, DSHP or SAP) was characterized. It is a 128 amino acid (aa) protein, containing a single Src homology 2 (SH2) domain. It interacts with signaling lymphocytic activation molecule (SLAM) expressed on the surface of activated T and B cells. We show that activated T, but not activated B, cells express the SH2D1A protein. NK cells express the protein as well. Tumor lines originating from B, T or NK cells exhibited similar SH2D1A protein expression as the corresponding normal cells, with some notable exceptions. EBV-carrying, tumor phenotype representative (type I), but not EBV-carrying lymphoblastoid cell line (LCL)-like (type III) or EBV-negative Burkitt lymphoma (BL) lines expressed SH2D1A. The phenotypic switch from type I to type III in the EBV-carrying BL line Mutu was associated with a down-regulation of SH2D1A and up-regulation of SLAM. In contrast to normal ex vivo and long-term activated NK cells, 2 of 3 NK leukemia lines expressed SLAM. All 3 lines expressed SH2D1A, like their normal counterparts. (C) 2000 Wiley-Liss, Inc.",
author = "No{\'e}mi Nagy and Cristina Cerboni and Karin Mattsson and Akihiko Maeda and P. Gogol{\'a}k and J{\'a}nos S{\"u}megi and A. L{\'a}nyi and L{\'a}szl{\'o} Sz{\'e}kely and Ennio Carbone and George Klein and Eva Klein",
year = "2000",
doi = "10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#",
language = "English",
volume = "88",
pages = "439--447",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - SH2D1A and slam protein expression in human lymphocytes and derived cell lines

AU - Nagy, Noémi

AU - Cerboni, Cristina

AU - Mattsson, Karin

AU - Maeda, Akihiko

AU - Gogolák, P.

AU - Sümegi, János

AU - Lányi, A.

AU - Székely, László

AU - Carbone, Ennio

AU - Klein, George

AU - Klein, Eva

PY - 2000

Y1 - 2000

N2 - The gene defect responsible for the X-linked lymphoproliferative disease (XLP) is associated with an impaired control of Epstein-Barr virus (EBV) infection. The gene has been recently identified and the encoded protein (designated SH2D1A, DSHP or SAP) was characterized. It is a 128 amino acid (aa) protein, containing a single Src homology 2 (SH2) domain. It interacts with signaling lymphocytic activation molecule (SLAM) expressed on the surface of activated T and B cells. We show that activated T, but not activated B, cells express the SH2D1A protein. NK cells express the protein as well. Tumor lines originating from B, T or NK cells exhibited similar SH2D1A protein expression as the corresponding normal cells, with some notable exceptions. EBV-carrying, tumor phenotype representative (type I), but not EBV-carrying lymphoblastoid cell line (LCL)-like (type III) or EBV-negative Burkitt lymphoma (BL) lines expressed SH2D1A. The phenotypic switch from type I to type III in the EBV-carrying BL line Mutu was associated with a down-regulation of SH2D1A and up-regulation of SLAM. In contrast to normal ex vivo and long-term activated NK cells, 2 of 3 NK leukemia lines expressed SLAM. All 3 lines expressed SH2D1A, like their normal counterparts. (C) 2000 Wiley-Liss, Inc.

AB - The gene defect responsible for the X-linked lymphoproliferative disease (XLP) is associated with an impaired control of Epstein-Barr virus (EBV) infection. The gene has been recently identified and the encoded protein (designated SH2D1A, DSHP or SAP) was characterized. It is a 128 amino acid (aa) protein, containing a single Src homology 2 (SH2) domain. It interacts with signaling lymphocytic activation molecule (SLAM) expressed on the surface of activated T and B cells. We show that activated T, but not activated B, cells express the SH2D1A protein. NK cells express the protein as well. Tumor lines originating from B, T or NK cells exhibited similar SH2D1A protein expression as the corresponding normal cells, with some notable exceptions. EBV-carrying, tumor phenotype representative (type I), but not EBV-carrying lymphoblastoid cell line (LCL)-like (type III) or EBV-negative Burkitt lymphoma (BL) lines expressed SH2D1A. The phenotypic switch from type I to type III in the EBV-carrying BL line Mutu was associated with a down-regulation of SH2D1A and up-regulation of SLAM. In contrast to normal ex vivo and long-term activated NK cells, 2 of 3 NK leukemia lines expressed SLAM. All 3 lines expressed SH2D1A, like their normal counterparts. (C) 2000 Wiley-Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033814931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033814931&partnerID=8YFLogxK

U2 - 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#

DO - 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#

M3 - Article

C2 - 11054674

AN - SCOPUS:0033814931

VL - 88

SP - 439

EP - 447

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -